NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double ...
NEO212™ completes initial two cohorts of Phase 1 study under FDA Investigative New Drug (IND). Study tests the safety of NeOnc’s patented novel drug, NEO212™, which is the bioconjugation of its leading drug candidate NEO100™ and Temozolomide (TMZ). As an …